Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (973) 973
science & technology (874) 874
life sciences & biomedicine (866) 866
myeloablative agonists - therapeutic use (759) 759
male (701) 701
female (694) 694
hematology (678) 678
transplantation (623) 623
adult (567) 567
middle aged (544) 544
immunology (463) 463
transplantation conditioning - methods (434) 434
transplantation, homologous (405) 405
adolescent (386) 386
hematopoietic stem cells (340) 340
hematopoietic stem cell transplantation (336) 336
stem cells (332) 332
aged (319) 319
treatment outcome (316) 316
hematology, oncology and palliative medicine (315) 315
survival analysis (285) 285
oncology (277) 277
retrospective studies (272) 272
child (266) 266
biological and medical sciences (236) 236
medical sciences (236) 236
transplantation conditioning (232) 232
hematopoietic stem cell transplantation - methods (219) 219
child, preschool (218) 218
myeloablative agonists - administration & dosage (182) 182
young adult (182) 182
vidarabine - analogs & derivatives (178) 178
graft vs host disease - prevention & control (177) 177
recurrence (170) 170
hematopoietic stem cell transplantation - adverse effects (167) 167
myeloablative agonists - adverse effects (163) 163
analysis (162) 162
infant (158) 158
hematologic neoplasms - therapy (153) 153
graft vs host disease - mortality (144) 144
health aspects (142) 142
care and treatment (141) 141
transplantation, autologous (138) 138
bone marrow (137) 137
disease-free survival (136) 136
graft vs host disease - immunology (131) 131
vidarabine - therapeutic use (128) 128
mortality (127) 127
transplantation conditioning - adverse effects (126) 126
immunosuppressive agents - therapeutic use (122) 122
risk factors (122) 122
cancer (120) 120
biophysics (119) 119
stem cell transplantation (117) 117
prognosis (116) 116
busulfan - therapeutic use (112) 112
leukemia, myeloid, acute - therapy (111) 111
hematologic and hematopoietic diseases (109) 109
melphalan - therapeutic use (108) 108
graft vs host disease - pathology (106) 106
anesthesia. intensive care medicine. transfusions. cell therapy and gene therapy (102) 102
transfusions. complications. transfusion reactions. cell and gene therapy (102) 102
bone marrow, stem cells transplantation. graft versus host reaction (101) 101
cyclophosphamide - therapeutic use (100) 100
busulfan - administration & dosage (98) 98
follow-up studies (96) 96
unrelated donors (96) 96
hematologic neoplasms - immunology (95) 95
graft vs host disease - etiology (93) 93
histocompatibility testing (93) 93
hematologic neoplasms - mortality (92) 92
antineoplastic combined chemotherapy protocols - therapeutic use (91) 91
chemotherapy (91) 91
prospective studies (90) 90
leukemia (89) 89
remission induction (87) 87
busulfan (85) 85
research (83) 83
acute disease (82) 82
survival rate (82) 82
siblings (81) 81
hematologic neoplasms - pathology (77) 77
pediatrics (77) 77
combined modality therapy (76) 76
patient outcomes (76) 76
graft survival (75) 75
hematopoietic stem cell transplantation - mortality (74) 74
time factors (74) 74
whole-body irradiation (69) 69
dosage and administration (68) 68
abridged index medicus (67) 67
bone marrow transplantation (66) 66
leukemia, myeloid, acute - mortality (66) 66
multiple myeloma - therapy (66) 66
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (65) 65
multiple myeloma (63) 63
cyclophosphamide (62) 62
t cells (61) 61
melphalan - administration & dosage (59) 59
medical colleges (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (978) 978
French (5) 5
Russian (3) 3
Spanish (3) 3
Chinese (1) 1
Czech (1) 1
Danish (1) 1
German (1) 1
Hungarian (1) 1
Japanese (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol
by Ferrari, S and Sundby Hall, K and Luksch, R and Tienghi, A and Wiebe, T and Fagioli, F and Alvegard, T.A and Brach del Prever, A and Tamburini, A and Alberghini, M and Gandola, L and Mercuri, M and Capanna, R and Mapelli, S and Prete, A and Carli, M and Picci, P and Barbieri, E and Bacci, G and Smeland, S
Annals of oncology, ISSN 0923-7534, 05/2011, Volume 22, Issue 5, pp. 1221 - 1227
chemotherapy-induced necrosis | Ewing sarcoma | high-dose chemotherapy | Chemotherapy-induced necrosis | High-dose chemotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Diseases of the osteoarticular system | Tumors of striated muscle and skeleton | Myeloablative Agonists - therapeutic use | Bone Neoplasms - mortality | Doxorubicin - therapeutic use | Bone Neoplasms - therapy | Sarcoma, Ewing - therapy | Humans | Child, Preschool | Male | Sarcoma, Ewing - mortality | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Young Adult | Dactinomycin - therapeutic use | Adult | Female | Child | Ifosfamide - therapeutic use | Busulfan - therapeutic use | Kaplan-Meier Estimate | Etoposide - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Peripheral Blood Stem Cell Transplantation | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning
by Kanakry, Christopher G and O'Donnell, Paul V and Furlong, Terry and De Lima, Marcos J and Wei, Wei and Medeot, Marta and Mielcarek, Marco and Champlin, Richard E and Jones, Richard J and Thall, Peter F and Andersson, Borje S and Luznik, Leo
Journal of clinical oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 31, pp. 3497 - 3505
Life Sciences & Biomedicine | Oncology | Science & Technology | Myeloablative Agonists - therapeutic use | Graft vs Host Disease - epidemiology | Busulfan - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Cyclophosphamide - therapeutic use | Incidence | Bayes Theorem | Adult | Female | Graft vs Host Disease - prevention & control | Aged | Transplantation Conditioning - methods | Index Medicus | ORIGINAL REPORTS | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ovarian function after hematopoietic cell transplantation: A descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning
by Phelan, R and Mann, E and Napurski, C and Defor, T.E and Petryk, A and Miller, W.P and Wagner, J.E and Verneris, M.R and Smith, A.R
Bone marrow transplantation (Basingstoke), ISSN 0268-3369, 10/2016, Volume 51, Issue 10, pp. 1369 - 1375
Immunology | Life Sciences & Biomedicine | Hematology | Oncology | Transplantation | Biophysics | Science & Technology | Humans | Middle Aged | Ovary - physiology | Myeloablative Agonists | Young Adult | Pilot Projects | Adolescent | Hematopoietic Stem Cell Transplantation - adverse effects | Leuprolide - therapeutic use | Follicle Stimulating Hormone - blood | Adult | Female | Ovary - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Child | Gonadotropin-Releasing Hormone - agonists | Ovarian Function Tests | Chemotherapy | Usage | Follicle-stimulating hormone | Cancer cells | Research | Hematopoietic stem cells | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation
by Luksch, R and Tienghi, A and Hall, K. Sundby and Fagioli, F and Picci, P and Barbieri, E and Gandola, L and Eriksson, M and Ruggieri, P and Daolio, P and Lindholm, P and Prete, A and Bisogno, G and Tamburini, A and Grignani, G and Abate, M.E and Podda, M and Smeland, S and Ferrari, S
Annals of oncology, ISSN 0923-7534, 11/2012, Volume 23, Issue 11, pp. 2970 - 2976
total-lung irradiation | lung metastases | Ewing's sarcoma | high-dose chemotherapy | Lung metastases | Total-lung irradiation | High-dose chemotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Pharmacology. Drug treatments | Diseases of the osteoarticular system | Tumors of striated muscle and skeleton | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pneumology | Myeloablative Agonists - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Bone Neoplasms - therapy | Sarcoma, Ewing - therapy | Humans | Bone Neoplasms - secondary | Child, Preschool | Lung Neoplasms - radiotherapy | Male | Antineoplastic Agents - therapeutic use | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Stem Cell Transplantation | Young Adult | Lung Neoplasms - secondary | Neoplasm Metastasis - drug therapy | Adult | Female | Child | Ifosfamide - therapeutic use | Busulfan - therapeutic use | Neoplasm Metastasis - radiotherapy | Etoposide - therapeutic use | Combined Modality Therapy | Lung Neoplasms - therapy | Sarcoma, Ewing - drug therapy | Sarcoma, Ewing - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Sarcoma, Ewing - radiotherapy | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | total-lung | Klinisk medicin | Cancer and Oncology | irradiation | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Current Use and Trends in Hematopoietic Cell Transplantation in the United States
by D'Souza, Anita and Lee, Stephanie and Zhu, Xiaochun and Pasquini, Marcelo
Biology of blood and marrow transplantation, ISSN 1083-8791, 2017, Volume 23, Issue 9, pp. 1417 - 1421
Hematology, Oncology and Palliative Medicine | HCT activity | Trends | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Hematologic Neoplasms - mortality | Humans | Transplantation, Autologous | Hematologic Neoplasms - pathology | Methotrexate - therapeutic use | Transplantation, Homologous | Hematopoietic Stem Cells - immunology | Graft vs Host Disease - mortality | Antilymphocyte Serum - therapeutic use | Adult | Transplantation Conditioning - methods | Child | Hematopoietic Stem Cell Transplantation - trends | Histocompatibility Testing | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Tissue Donors - classification | Calcineurin Inhibitors - therapeutic use | Hematopoietic Stem Cells - cytology | Survival Analysis | Graft vs Host Disease - prevention & control | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Alemtuzumab - therapeutic use | Tissue Donors - supply & distribution | Bone marrow | Analysis | Hematopoietic stem cells | Medical colleges | Medical research | Medicine, Experimental | Index Medicus | trends
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis
by Jain, Tania and Kunze, Katie L and Temkit, M’hamed and Partain, Daniel K and Patnaik, Mrinal S and Slack, James L and Khera, Nandita and Hogan, William J and Roy, Vivek and Noel, Pierre and Leis, Jose F and Sproat, Lisa Z and Fauble, Veena and Mesa, Ruben A and Palmer, Jeanne
Bone marrow transplantation (Basingstoke), ISSN 0268-3369, 02/2019, Volume 54, Issue 2, pp. 204 - 211
Immunology | Life Sciences & Biomedicine | Hematology | Oncology | Transplantation | Biophysics | Science & Technology | Myeloablative Agonists - therapeutic use | Primary Myelofibrosis - mortality | Myeloablative Agonists - adverse effects | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Transplantation Conditioning - mortality | Transplantation, Homologous | Carmustine - therapeutic use | Antineoplastic Agents - adverse effects | Adult | Female | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Busulfan - therapeutic use | Primary Myelofibrosis - complications | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Transplantation Conditioning - standards | Survival Analysis | Aged | Primary Myelofibrosis - therapy | Chimerism | Hematopoietic Stem Cell Transplantation - methods | Care and treatment | Myelofibrosis | Patient outcomes | Stem cells | Development and progression | Methods | Stem cell transplantation | CD3 antigen | Patients | Hematopoietic stem cells | Hemopoiesis | Urea | Fludarabine | Melphalan | Busulfan | Conditioning | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia
by Saraceni, Francesco and Beohou, Eric and Labopin, Myriam and Arcese, William and Bonifazi, Francesca and Stepensky, Polina and Aljurf, Mahmoud and Bruno, Benedetto and Pioltelli, Pietro and Passweg, Jakob and Sociè, Gerard and Santarone, Stella and Yakoub‐Agha, Ibrahim and Lanza, Francesco and Savani, Bipin N and Mohty, Mohamad and Nagler, Arnon and European Soc Blood Marrow and Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
American journal of hematology, ISSN 0361-8609, 10/2018, Volume 93, Issue 10, pp. 1211 - 1219
Life Sciences & Biomedicine | Hematology | Science & Technology | Myeloablative Agonists - therapeutic use | Thiotepa - therapeutic use | Confidence Intervals | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Myeloablative Agonists - adverse effects | Thiotepa - administration & dosage | Humans | Middle Aged | Drug Evaluation | Male | Living Donors | Busulfan - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Allografts | Bone Marrow Transplantation | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Transplantation Conditioning - adverse effects | Retrospective Studies | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Siblings | Busulfan - adverse effects | Busulfan - therapeutic use | Vidarabine - adverse effects | Proportional Hazards Models | Combined Modality Therapy | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Myeloablative Agonists - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Thiotepa - adverse effects | Cyclophosphamide | Transplantation | Comparative analysis | Thiotepa | Stem cells | Fludarabine | Cord blood | Donors | Transplants & implants | Myeloid leukemia | Leukemia | Remission | Busulfan | Acute myeloid leukemia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Cidofovir in the Treatment of BK Virus–Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation
by Philippe, Michael and Ranchon, Florence and Gilis, Lila and Schwiertz, Vérane and Vantard, Nicolas and Ader, Florence and Labussiere-Wallet, Hélène and Thomas, Xavier and Nicolini, Franck-Emmanuel and Wattel, Eric and Ducastelle-Leprêtre, Sophie and Barraco, Fiorenza and Lebras, Laure and Salles, Gilles and Michallet, Mauricette and Rioufol, Catherine
Biology of blood and marrow transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 4, pp. 723 - 730
Hematology, Oncology and Palliative Medicine | Cidofovir | BK virus | Hemorrhagic cystitis | Hematopoietic stem cell transplantation | Transplantation | Immunology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Polyomavirus Infections - immunology | Cytosine - analogs & derivatives | Polyomavirus Infections - etiology | BK Virus - drug effects | Hematologic Neoplasms - mortality | Humans | Middle Aged | Hemorrhage - mortality | Cystitis - immunology | Male | Hematologic Neoplasms - pathology | Transplantation, Homologous | Hemorrhage - etiology | Hematopoietic Stem Cell Transplantation - adverse effects | Tumor Virus Infections - immunology | Tumor Virus Infections - therapy | Adult | Female | Cytosine - therapeutic use | Retrospective Studies | Cystitis - etiology | Glomerular Filtration Rate | Drug Administration Schedule | Organophosphonates - therapeutic use | Antiviral Agents - therapeutic use | Hemorrhage - therapy | Hemorrhage - immunology | Cystitis - therapy | Graft Survival | Tumor Virus Infections - mortality | Cystitis - mortality | Polyomavirus Infections - mortality | Polyomavirus Infections - therapy | Survival Analysis | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning | Tumor Virus Infections - etiology | Viral Load - drug effects | BK Virus - physiology | Care and treatment | Cystitis | Hematopoietic stem cells | Stem cells | Medical research | Leptin | Medicine, Experimental | Epstein-Barr virus | Index Medicus | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients
by Cibeira, Maria Teresa and Sanchorawala, Vaishali and Seldin, David C and Quillen, Karen and Berk, John L and Dember, Laura M and Segal, Adam and Ruberg, Frederick and Meier-Ewert, Hans and Andrea, Nancy T and Sloan, J. Mark and Finn, Kathleen T and Doros, Gheorghe and Blade, Joan and Skinner, Martha
Blood, ISSN 0006-4971, 10/2011, Volume 118, Issue 16, pp. 4346 - 4352
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Biological and medical sciences | Medical sciences | Myeloablative Agonists - therapeutic use | Amyloidosis - therapy | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Transplantation, Autologous | Treatment Outcome | Amyloidosis - drug therapy | Hematologic Tests | Antineoplastic Agents, Alkylating - administration & dosage | Melphalan - therapeutic use | Immunoglobulin Light Chains - metabolism | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Melphalan - administration & dosage | Aged, 80 and over | Myeloablative Agonists - administration & dosage | Adult | Female | Aged | Amyloidosis - metabolism | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia | Clinical Trials and Observations | Transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text A comparison of immune reconstitution and graft‐versus‐host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients
by Geyer, Mark B and Jacobson, Judith S and Freedman, Jason and George, Diane and Moore, Virginia and van de Ven, Carmella and Satwani, Prakash and Bhatia, Monica and Garvin, James H and Bradley, Mary Brigid and Harrison, Lauren and Morris, Erin and Della‐Latta, Phyllis and Schwartz, Joseph and Baxter‐Lowe, Lee A and Cairo, Mitchell S
British journal of haematology, ISSN 0007-1048, 10/2011, Volume 155, Issue 2, pp. 218 - 234
paediatrics | graft‐versus‐host disease | immune | cord blood transplantation | immunology | Graft-versus-host disease | Immunology | Immune | Paediatrics | Cord blood transplantation | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Biological and medical sciences | Medical sciences | Myeloablative Agonists - therapeutic use | Recombinant Proteins - therapeutic use | Whole-Body Irradiation | Antibodies, Neoplasm - therapeutic use | Cyclophosphamide - administration & dosage | Graft vs Host Disease - epidemiology | Neoplasms - surgery | Humans | Child, Preschool | Male | Antibiotic Prophylaxis | Melphalan - therapeutic use | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Busulfan - administration & dosage | Cyclophosphamide - therapeutic use | Transplantation, Homologous | Antibodies, Monoclonal, Humanized - administration & dosage | Female | Leukocyte Count | Retrospective Studies | Transplantation Conditioning - methods | Child | Graft vs Host Disease - etiology | Antibodies, Monoclonal, Humanized - therapeutic use | Busulfan - therapeutic use | T-Lymphocytes | Neutrophils | Graft Survival | Vidarabine - analogs & derivatives | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Vidarabine - therapeutic use | Granulocyte Colony-Stimulating Factor - therapeutic use | Cord Blood Stem Cell Transplantation - methods | Melphalan - administration & dosage | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Antilymphocyte Serum | Genetic Diseases, Inborn - surgery | Vidarabine - administration & dosage | Pediatrics | Immunoglobulins | Immunotherapy | Stem cells | Transplantation | Comparative analysis | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights